Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

The trial failed to achieve statistical significance in its goal of improved MCCB neurocognitive composite scores.

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...

Sage Therapeutics, Inc. announced today topline results from LIGHTWAVE, a 12- week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor in ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...